Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Breast Cancer, Hormonreceptor Positive, Her2-normal, Postneoadjuvant Treatment With CDK 4/6 Inhibitor, CPS-EG Score
Interventions: Palbociclib PD-0332991, Placebo; Drug
Lead sponsor: GBG Forschungs GmbH; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
Interventions: ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab; Biological
Lead sponsor: Simcha IL-18, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, High Grade B-Cell Lymphoma, Not Otherwise Specified, Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma
Interventions: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide, Etoposide, Fludarabine Phosphate; Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Autism Spectrum Disorder, Autism
Interventions: Early Diagnostic Response Model Expanded; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 16 Months to 36 Months
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
Interventions: arsenic trioxide, ascorbic acid, dexamethasone, thalidomide, anti-cytokine therapy, antiangiogenesis therapy, biological therapy, chemotherapy, drug resistance inhibition, growth factor antagonist therapy, non-specific immune-modulator therapy; Drug · Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: High Grade Glioma, Anaplastic Astrocytoma
Interventions: DB107-RRV, DB107-FC; Drug
Lead sponsor: Ashish Shah; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain)
Interventions: Artesunate Suppositories; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Towson, Maryland

Conditions: High and Increasing Contribution of Energy From Beverages in the Diet May Enhance Positive Energy Balance and Weight Gain
Interventions: liquid to liquid, liquid to solid, solid to liquid, solid to solid; Behavioral
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Obesity
Interventions: Sonosite S-Nerve® US system (SonoSite, Bothell,WA); Device
Lead sponsor: Manuel C. Vallejo; Other
Eligibility: 14 Years to 55 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: NeuVax vaccine, Trastuzumab, GM-CSF; Biological · Drug
Lead sponsor: Cancer Insight, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 24
States / cities: Santa Monica, California • Santa Rosa, California • Washington D.C., District of Columbia + 18 more

Conditions: Multiple Myeloma
Interventions: High-Dose Melphalan HCL for Injection (Propylene Glycol-Free), Autologous Transplantation; Drug · Other
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: Up to 70 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 6
States / cities: Chicago, Illinois • Fairway, Kansas • Worcester, Massachusetts + 3 more

Conditions: Brain and Central Nervous System Tumors, Metastatic Cancer
Interventions: iodine I 131 monoclonal antibody 81C6; Radiation
Lead sponsor: Duke University; Other
Eligibility: 3 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Opioid Use Disorder, Pregnancy Related, Pregnancy, High Risk, Pregnancy Complications, Buprenorphine Withdrawal
Interventions: Buprenorphine Transdermal Matrix Patch, Sham patch; Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 110 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alzheimer's Disease
Interventions: Flortaucipir F18; Drug
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 60 Years to 89 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Phoenix, Arizona • San Francisco, California

Conditions: Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes
Interventions: Lorcaserin hydrochloride, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 14,673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 373
States / cities: Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more

Conditions: Depression, Anxiety
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS); Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 60 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Glaucoma
Interventions: Glaucoma screening with optical coherence tomography (OCT), color fundus photography, and tonometry, Educational Brochure; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Fremont, California • Oakland, California • San Francisco, California

Conditions: Alcoholism
Interventions: Benfotiamine, Placebo; Drug
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Non-Muscle- Invasive Bladder Cancer
Interventions: Durvalumab, BCG; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 19
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 16 more

Conditions: Obesity
Interventions: protein and meal frequency; Other
Lead sponsor: Skidmore College; Other
Eligibility: 30 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Saratoga Springs, New York

Conditions: Prostate Cancer
Interventions: Abiraterone Acetate, Prednisone, Enzalutamide, LHRHa; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colon Cancer Prevention
Interventions: High chlorophyll diet - intervention 1st, High chlorophyll diet - control 1st; Behavioral
Lead sponsor: Auburn University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: B-cell Lymphoma
Interventions: Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 5
States / cities: Gilbert, Arizona • Duarte, California • Tampa, Florida + 2 more

Conditions: Neuroblastoma, Sarcoma, Rhabdomyosarcoma-Embryonal, Rhabdomyosarcoma- Alveolar, Neuroectodermal Tumors, Primitive, Peripheral
Interventions: Tumor Purged/CD25 Depleted Lymphocytes, Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine, rhIL-7, Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Months to 35 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Early Diagnostic Telehealth Pilot for Moderate- and High-Risk Children: Evaluating Assessment Protocols and Efficiency in Georgia's Early Intervention Program

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

Effects of Food Form and Fitness on Appetite and Digestion.

A Novel Way to Estimate Epidural Depth in Morbidly Obese Parturient

Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients

Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers

Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)

18F-AV-1451 High Resolution Autopsy Study

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Brief, High-dose rTMS for Depression

Glaucoma Screening to Enhance At-Risk Californians' Health

High Dose Vitamin B1 to Reduce Abusive Alcohol Use

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

Increased Dietary Protein and Meal Frequency Reduces Total and Abdominal Body Fat During Weight Maintenance and Weight Loss

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

Exploring the Effects of a High Chlorophyll Dietary Intervention to Reduce Colon Cancer Risk in Adults

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma